Get Personalized Email...Today! Mailbank.com

Stocktraders-ICQ.com©

by M_A_Trader© ; & TraderJ©

2001

Welcome to Our stocktraders-icq.com© Website.

WARNING – After-hours investing involves unique risks. These risks may include greater price volatility, less liquidity, and wider bid/ask spreads than during regular market hours.

The Week Past

Well, we had the Dow up last week by finishing +4.4% for the week, the Nasdaq finished the week +4.3%, The S & P 500 was +3.7%, and the Russell 2000 was +?%. All traders should pay closer attention to their mental stops or plan on riding out some bumps along the way.

YTD

Dow +4.6%

Nasdaq -10.8%

S & P 500 -2.18%

Russell 2000 +?%

This last week was a medium upturn for the Dow and a medium upturn for the Nasdaq. We believe margin is fine to use if you DO NOT margin all your holdings. We feel it would be prudent to have 1/2 of an account on margin at this time.

We believe that a long-term or swing-trader should have 1/3 of their portfolio on margin at this time. A daytrader could have some margin of up to 1/2 of his holdings if you use tight stops. We want short-term traders to have their stops in a tighter range of –5% to -10% We suggest using -20% stops on your long-term positions at this time.

Well, the Dow was down small and the Nasdaq finished the week down large.

Economic Reports

Last Weeks Economic News

The Economic reports coming this week are: on May 14th at 8:30 AM EST the Business Inventories report will be released and at 9:15 AM EST the Industrial Production report will be released; on May 15th at 2:15 PM EST The FED will release their report on interest rates and what they will be lowering interest rates too; on May 16th at 8:30 AM EST the Housing Starts and Building Permits reports will be released and at 8:30 AM EST the Consumer Price Index (CPI) report will be released; on May 17th at 8:30 AM EST the Initial Claims report on joblessness will be released; and on May 18th at 8:30 AM EST the International Trade report will be released.

This Weeks Economic News

The reports are: on May 24th at 8:30 Am EST the Initial Claims on joblessness report will be released and at 10:00 Am EST the New Homes Sales report will be released and on May 25th at 8:30 AM EST the Durable Goods Orders report will be released, at 8:30 AM EST the Gross Domestic Product (GDP) report will be released, and at 10:00 AM EST the Existing Home Sales report will be released. These reports will rate a C to B on a scale of A-F. Everyone should place close attention to pre-market trading and how the futures are acting each morning before the market opens for trading.

Ipos

IPOs by M_A_Trader©:

Ipos are not coming out now as the market goes lower. There will not be many ipos coming to the market so check them out on at this web site. Click on Ipo Info is a great site to research ipos.WARNING: IF YOU BUY IPOs AFTER THE STOCK OPENS USE LIMIT ORDERS ONLY.

Stock Rumors

We have heard FRONTIER OIL CORPORATION (NYSE: FTO) may become a takeover candidate at $15-16. This stock would be a very speculative play in the energy sector. Buy under $9 with a mental stop at $6 ½. Well, FTO is at $12.45 on May 15th so we would recommend a trader sell ¼ of their holdings and take some profits off the table if they bought below $9. Hold the rest for our $16 target and move the stop up to $11.75. Only use money you can afford to lose all of it in this type of trade.

FTO hit our stop of $11.75 on May 23, 2001 so if you still hold some FTO you should have been stopped out at a nice gain.

The FED

The FED cut rates 50 basis points on May 15, 2001. The Fed will next meet on June 26-27, 2001.

"A" Portfolio

”A” Portfolio Stock Report by M_A_Trader©

We are looking at adding the following stocks to the “A” Portfolio: AAPL at $24 or less and more MDT at $42 or less.

We added MDT at $41.25 and AAPL at $23.25 to the “A” Portfolio on May 23rd, 2001.

AAPL ($23.05) designs, manufactures and markets personal computers and related personal computing and communicating solutions for the sale primarily to education, creative, consumer, and business customers. For the 6 months ended 3/31/01, revenues fell 43% to $2.44B. Net loss before acct. change totaled $164M, vs. an income of $416M. Revenuesreflect a decline in worldwide demand for the Company's products. Loss reflects rebate programs and price cuts. AAPL

We added MDT at $43.86; ISIL at $29.75; RETK at $29.75; and CTLM at $30.75 to our “A” Portfolio.

Here is some information on the above four stocks.

MDT ($41.88): Medtronic, Inc. News for MDT: “MINNEAPOLIS--(BUSINESS WIRE)--May 22, 2001-- Pre-charge diluted earnings-per-share growth for the fourth quarter and for fiscal year 2001 was 15 percent and 17 percent, respectively Medtronic, Inc. (NYSE:MDT), today reported that annual pre-charge net earnings grew for the 16th consecutive year to 1.282 billion, or 1.05 per diluted share, up 17 percent from the 0.90 pre-charge, diluted earnings-per-share recorded in fiscal year 2000. After non-recurring, pre-tax charges of 53.4 million taken during the year, net earnings were 1.246 billion, or 1.02 per diluted share. The company also reported record revenues of 5.552 billion for fiscal year 2001. This represents a 14-percent increase, on a constant currency basis, over the 5.016 billion recorded the previous year. Foreign exchange translation reduced annual revenue by 149 million and the growth rate to 11 percent. "All four of our businesses reported record earnings and revenues for the fourth quarter and fiscal year 2001, and the company is well-positioned for continuing growth," said Art Collins, president and chief executive officer. "New growth platforms include advances in the treatment of heart failure, atrial fibrillation, coronary artery disease, Parkinson's disease and spinal disorders, to name a few. These advancements underscore the strength of Medtronic's development efforts and new product pipeline. "Results from the past year reflect a more diversified and balanced growth profile for Medtronic," added Collins. "The acquisitions made over the last several years accounted for more than 30 percent of our revenues in fiscal 2001. These new businesses, combined with the acceleration of our product development efforts, provide the company with multiple avenues for future growth." For the year's fourth quarter, pre-charge earnings were 0.30 per diluted share, a 15-percent increase over the pre-charge earnings-per-share of the comparable period last year. Pre-charge net earnings were 363.6 million, an increase of 15 percent over the 317.0 million pre-charge net earnings reported in the fourth quarter of fiscal 2000. Quarterly revenues totaled 1.518 billion, growth of 9 percent on a constant-currency basis. Foreign currency translation impacted comparisons to last year's fourth quarter by 44 million, reducing the reported revenue growth rate to 6 percent. In addition, the company announced plans to further streamline its operations, which will result in a total pre-tax restructuring charge of 47 million to 52 million, of which 14.5 million was recognized in the fourth quarter of fiscal 2001. The fourth-quarter results also include a 7.6 million non-recurring legal settlement. Fourth-quarter charges reduced reported quarterly earnings to 349.6 million and 0.29 per diluted share.” MDT

CTLM: Centillium Communications. News for CTLM ($30.15): No new news for CTLM CTLM

ISIL ($36.49): ISIL News for ISIL: “IRVINE, Calif.--(BUSINESS WIRE)--May 23, 2001-- -- Three versions (10, 12 and 14 bit) with maximum clock speed of 130 MHz -- New digital-to-analog converter supports all 2.5G and 3G cellular protocols Intersil Corporation (Nasdaq:ISIL), a leading developer of silicon technology for wireless infrastructure, announced today a new series of next-generation CommLink(TM) high-speed digital-to-analog-converters (DACs) that support the development of high-performance wireless communications products. The new DACs can be integrated into a wide range of products including cellular base stations, high-end test equipment, medical imaging, emergency location services, satellite terminal equipment and point-to-point and point-to-multi-point wireless access terminals. Additionally, Intersil's new ISL5X61 DACs support all current and next generation cellular protocols. Traditionally, high dynamic range wireless communications applications require the adjustment - occasionally manual adjustment - of setup and hold timing in order to optimize the level of spurious free dynamic range (SFDR) performance in the overall signal chain. The ISL5X61 series delivers increased levels of SFDR stability across setup and hold timing on the input, imposing less stringent requirements on input timing and simplifying overall transmitter design. The devices also feature low power consumption (less than 100mW at maximum update rate) and sleep mode capability, further reducing power consumption in idle channel conditions. "Intersil is a recognized leader in software defined radio for cellular infrastructure and during our efforts to develop DAC technology optimized for base station applications, we have created a device that also improves the data conversion process in a number of other demanding applications," said John Krehbiel, vice president of the CommLink product line at Intersil. "Our new DACs have broad appeal and enhance Intersil's ability to address the strong demand for high performance, high speed converters.”ISIL

RETK ($40.37): etek Inc. News for RETK: “MINNEAPOLIS, May 21 /PRNewswire/ -- Retek Inc. (Nasdaq: RETK), the leading provider of solutions that help the retail industry create, manage and fulfill consumer demand, today announced that Gap Inc. (NYSE: GPS) has selected its end-to-end predictive planning solutions to help decrease supply chain costs and increase customer service across its Gap, Banana Republic and Old Navy brands. With this announcement, Gap Inc. will harness Retek's planning solutions to optimize its pre-season and in-season planning process across all store formats, geographies and its supply chain. "Retek will help Gap Inc. optimize its supply chain by allowing it to plan at a level no other vendor can effectively provide," said Duncan Angove, general manager, supply chain solutions, Retek. "With our scalable, integrated planning solution, Retek is helping to fundamentally change the planning process." Traditionally, retailers have had to rely on broad financial plans as the basis for their business decisions. By increasing visibility to the behavior of individual items, Retek planning solutions allow a retailer to plan at a much more detailed level. By integrating accurate consumer demand forecasts with style/color plans at the week level, retailers such as Gap Inc. could realize unparalleled efficiency in the form of decreased inventory costs and enhanced revenue opportunities. "We are very impressed with Retek's comprehensive tool set and their understanding of what retailers like Gap Inc. are looking for in a planning solution," said Ken Harris, CIO, Gap Inc. "The Retek solution offers incredible functionality and integration. We are excited to uncover how this will help us better work with large volumes of data and improve forecast accuracy.” RETK

We have added AXP at $37.50; FRE at $60.50; and XLF at $25.50 to the “A” Portfolio the last few weeks . All three stocks are in the financial sector. Here is some information on all three companies.

AXP American Express ($46.05). News for AXP: No new news for AXP. AXP

FRE ($62.53) News for FRE: No new news for FRE. FRE

Financial Sel Sect Spdr Fd (AMEX: XLF $28.94) is a sector spider traded on the AMEX.

The upper resistance levels for the Nasdaq is 2,350 and then 2,575. Support is at 2,200 and then 2,100. We would like to see the Nasdaq stay above 2,100. The Dow has support at 11,000 and then 10,900. Resistance is at 11,300.

The “A” Portfolio is going to a strict percentage gain or loss sell mode for now with the market fluctuating so much at this time. If a position moves up +20% one-quarter of the position will be sold, at +40% another one-quarter will be sold, and then at +75 to +100% another one-quarter of the position will be sold. That will leave one-quarter of the position to ride the stock higher. We still will use –30% to exit a stock position. Our targets for these stocks are on our Charts page.

We will talk about more of the stocks in the “A” Portfolio in the coming weeks.

All the past additions to the “A” Portfolio are on this page now.”A” Portfolio Additions

Please read our disclaimer about the “A” Portfolio here. ”A” Portfolio Disclaimer

Stock Charts for 2000 and 2001

The Charts page will be up and running by the end of May 2001.This page has links to all our stock charts and “A” Portfolio results for 2001.The Charts

Canadian Stocks

After we turn from overall market downward momentum to upward momentum these two Canadian companies should rebound well.

Infowave Wireless (IW:TORONTO) Target US$30 Infowave is well positioned to take advantage of the coming boom in wireless email. Thomas Koll(a current VP at Microsoft) will be starting as the companies CEO on February 15. They have many impressive partners including Intel, Nokia and Compaq. Current market conditions have made this stock very oversold.

Rogers Communications (RCB.A:TORONTO) Target US$42 Rogers is Canada's largest cable television company they also have their hands into providing high speed internet as well as cellular and paging services. The long-term outlook for this company is stable and is likely to see steady growth in a booming industry.

Leaps

LEAPS® information is now on this page. LEAPS®

Stocks We Like

Research in Motion closed the week at $39.69 we have lowered our 12 month target to $155 (RIM, TSE) (RIMM, NASDAQ). News for RIMM: We are letting RIMM run for our target of $155. Since we already have PALM a trader may want to add HAND and have all three in their portfolio.We added RIMM at $40 ¼ and today March 28th we added more RIMM at $20.You may have to hold RIMM for 12 – 18 months depending on how the market is doing. RIMM has found partners in AOL and Compaq. Amazon has Crackberry available for $499 with service available at $39.95 per month. News for RIMM: “WATERLOO, ON, May 17 /PRNewswire/ - Research In Motion Limited (RIM) (HYPERLINK "/cgi-bin/details?Symbol=RIMM"Nasdaq: RIMM TSE: RIM), a pioneer and world leader in the mobile communications market, today announced that it has filed a complaint for patent and trademark infringement against Glenayre Electronics, Inc. (Nasdaq: GEMS), a provider of personal telecommunication systems. The complaint was filed May 16, 2001 in the United States District Court for the District of Delaware. The complaint alleges that Glenayre has engaged in acts of patent infringement, trademark infringement, dilution, unfair competition and false advertising in connection with the development, marketing and sale of wireless handheld products. The complaint alleges that Glenayre's conduct violates federal patent law 35 U.S.C. 271, by infringing RIM's recently issued United States Patent No. 6,219,694. The patent relates to RIM's BlackBerry Single Mailbox Integration patent which covers a system and method invented by RIM that was commercialized as an important architectural element of RIM's award-winning BlackBerry wireless email solution. This action also alleges that Glenayre violates the Lanham Act (15 U.S.C. 1114 and 1125(a)) and the Delaware Deceptive Trade Practices Act (6 Del. C. 2531 et. seq.) for deceptive trade practices and unfair competition based upon Glenayre's unauthorized and willful use of designations and names confusingly similar to registered trademarks belonging to RIM. In its complaint, RIM seeks Glenayre to be found to have infringed on RIM's patent rights and that such conduct entitles RIM to preliminary and permanent injunctions barring Glenayre from continuing to infringe on RIM's patents. In addition RIM seeks to prevent Glenayre from using product designations that infringe on RIM's registered trademarks and also seeks injunctive relief, profits, damages, costs and legal fees for Glenayre's allegedly willful conduct.” RIMM

VIRS (5.00 ) is a very speculative buy at this time. VIRS is a strong buy if it sinks down to $5 1/2 – 6 1/2 Only buy it if you can afford to lose all you invest in it. The chart for VIRS is looking good so continue to hold this stock for our $25 target. News from VIRS: No new news for VIRS now.

Management and product development strategy is available on Triangle's website at: VIRS

We are adding another blown up stock as a speculative buy. We are adding ZOOX (2.88), as a very risky buy at $2 ½ or lower with a target of $29 in 24 months. ZOOX is currently having a slow down in sales year to year. Its new switch for SANS are not selling as well as management expected. New management has been installed but it may take two or more quarters to fix their inventory oversupply. Well, ZOOX has not been doing very good since we recommended it a few months ago. We would average into more of ZOOX and hold for the long-term. ZOOX may be dead money for the next two-three quarters. News for ZOOX this week: No new news for ZOOX. Only buy this stock if you can afford to lose your entire investment in ZOOX.ZOOX

Over the next few weeks we will talk about the stocks in our “A” Portfolio. We added more IMNX ($17.02) to our “A” Portfolio because they still will sell all the Enbrel they can produce and have a waiting list for Enbrel. IMNX News for IMNX this week: “MELBOURN, England, and SEATTLE, May 21 /PRNewswire/ -- Cambridge Antibody Technology (London: CAT) and Immunex Corporation (Nasdaq: IMNX) announce a broad product development collaboration committed to the joint discovery, development, marketing and sale of human antibody-based therapeutics for autoimmune and inflammatory disorders. Under the terms of the agreement, the two companies will share equal responsibility for all research and development, and split equally any potential profits generated by product sales. Immunex will contribute two undisclosed proprietary targets, scientific and development expertise to the partnership, while CAT will contribute its proprietary human antibody phage display technology and high throughput screening capabilities to identify human antibodies. "We are extremely pleased to be expanding our relationship with Immunex for the custom design and development of human antibody drugs," said Dr. David Chiswell, CAT Chief Executive Officer. "It is a further demonstration of CAT's commitment to share in the risks and rewards of antibody product development and to build a drug pipeline serving areas of significant unmet medical need." CAT will have primary responsibility for the discovery and optimization of human antibodies specific to the Immunex targets. Immunex will be primarily responsible for additional pre-clinical evaluation, clinical trials and product commercialization. "This new collaboration with CAT underscores our commitment to rapidly develop antibody based therapeutics to our validated proprietary targets. This agreement allows us to work with the skilled scientists and systems at CAT and to accelerate the development timelines on two important drug targets," said Douglas Williams, Ph.D., Immunex Executive Vice President and Chief Technology Officer. In November 2000, Immunex and CAT announced that Immunex received a license from CAT to utilize its antibody library for reagent generation and target validation. Under that agreement, Immunex will also receive up to eight exclusive product options derived from its in house use of the CAT library and CAT would potentially receive clinical milestones and royalty payments on sales.”

Corvis Corporation CORV ($7.35) News for CORV: No new news for CORV. CORV

Sycamore Networks (SCMR) ($11.10) News for SCMR: “HELMSFORD, Mass.--(BUSINESS WIRE)--May 23, 2001-- Demonstrates the potential of bandwidth on demand with emerging industry standard Sycamore Networks (NASDAQ: SCMR), a leader in intelligent optical networking, announced today that it will demonstrate successful implementation of the Optical Internetworking Forum (OIF) User Network Interface (UNI) 1.0 specification. The multi-vendor, multi-technology UNI interoperability demonstration will be held during SUPERCOMM 2001 in Atlanta, June 3-7 at Booth 150D. The demonstration will include Sycamore's SN 16000 intelligent optical switch as a core device, interconnecting with a variety of IP, edge and other systems. "As optical networks evolve to incorporate a greater level of intelligence and software functionality, the ability to dynamically establish optical circuits will dramatically enhance the service capabilities of the intelligent optical network," said Rick Barry, chief technology officer of Sycamore Networks, and OIF board member. "Sycamore is committed to providing customers with open, interoperable solutions that enable them to effectively transform the capacity of the optical core into new, revenue-generating network services." Beginning with its activity in the Optical Domain Service Interconnect (ODSI) coalition and continuing through its ongoing involvement in the OIF UNI 1.0 work, Sycamore continues to demonstrate its commitment to providing customers with the broadest range of interoperable solutions. OIF's Interoperability Demo The Optical Internetworking Forum (OIF) is sponsoring its first User Network Interface (UNI) Interoperability Demonstration at SUPERCOMM in booth 150D in the Georgia Dome. This demonstration highlights OIF's UNI Protocol that allows client devices to dynamically establish and tear down optical circuit connections. The achievement of UNI interoperability is the first step toward allowing carriers to offer advanced optical network services across multi-vendor, multi-technology networks. OIF is a rapidly growing non-profit organization with 350 member companies to date, including many of the world's leading carriers, component and system vendors. The purpose of the OIF is to accelerate the deployment of interoperable, cost effective, and robust optical internetworks and their associated technologies. More information on the OIF and the interoperability demo can be found at OIF

SCMR

Ceragon Networks Ltd. (CRNT $3.35) News for CRNT: “TEL AVIV, Israel--(BUSINESS WIRE)--May 23, 2001--Ceragon Networks Ltd. (Nasdaq:CRNT), a global provider of high-capacity broadband wireless systems for next generation communications networks, today announced the first deployment of its high-capacity FibeAir systems with a major operator of GSM mobile communications in China. The equipment is being supplied through Beijing P-COM, a Ceragon strategic partner. Ceragon's FibeAir product family offers a unique solution for the cellular market that includes access and transport applications. Designed to offer a variety of frequencies and modulation schemes, Ceragon's systems enable the flexibility required of today's full-scale cellular networks. Together with P-COM, Ceragon has provided a high-performance, cost effective solution for China's GSM network infrastructure. Ceragon's FibeAir systems, operating in the 18 GHz frequency band, have been deployed as an STM-1 backbone for the cellular network infrastructure. FibeAir systems are deployed in a ring topology, providing high-capacity connectivity between base stations and PDH hubs within the GSM network located in Tianjing, China's fifth largest city. Providing data and voice transport for subscribers, P-COM's PDH systems have been deployed in the 15 GHz frequency band, offering access for remote base stations. "We are proud to be selected by China's leading cellular telecommunications provider for our first major cellular network in this region," said Shraga Katz, Ceragon Networks' president and CEO. "Our strategic alliance with P-COM enables us to provide cellular operators in China with a comprehensive solution including a wide range of equipment, services and support.” CRNT

Capstone Turbine Corp. CPST ($37.20) News for CPST: No new news for CPST. CPST

CORR ($36.25) News from CORR: “SOUTH SAN FRANCISCO, Calif. & KENILWORTH, N.J.--(BW HealthWire)--May 23, 2001-- COR Therapeutics, Inc. and Schering-Plough Corporation announce one-year results from the ESPRIT study Results announced today at a satellite symposium held in conjunction with the annual Paris Course on Revascularization in Paris, France showed that patients who received INTEGRILIN(r) during coronary stent procedures continued to benefit from a statistically significant reduction in the combined incidence of death or heart attack at one year compared to patients who received placebo. Results from the one-year analysis of the ESPRIT study showed that the combined incidence of death or heart attack was significantly reduced from 12.4 percent with placebo to 8.0 percent with INTEGRILIN (P 0.0010). The combined endpoint of death, heart attack, or target vessel revascularization at one year was also significantly reduced from 22.1 percent with placebo to 17.5 percent with INTEGRILIN (P0.0068). A consistency of benefit for all components of the study endpoint was demonstrated at 48 hours, 30 days, six months, and one year without any attenuation of effect. The incidence of heart attack at one year was reduced from 10.7 percent with placebo to 7.2 percent with INTEGRILIN--a 3.5 percentage point reduction, identical to that reported at 30 days and consistent with the 3.4 percentage point reduction seen at six months. The incidence of death at one year was reduced from 2.0 percent with placebo to 1.4 percent with INTEGRILIN--a 0.6 percentage point reduction as compared to a 0.2 percentage point reduction in death at 30 days and identical to the reduction reported at six months. "These findings clearly confirm our initial premise in conducting ESPRIT. When properly dosed, INTEGRILIN helps prevent the acute ischemic complications associated with coronary stent procedures. Importantly, this acute benefit results in a significant long-term reduction in death or heart attack," stated James E. Tcheng, MD, Associate Professor of Medicine at Duke University Medical Center in Durham, NC and Principal Investigator for the trial. "Given the affordable cost of therapy with INTEGRILIN, coupled with the demonstration of durable long-term benefits, there remain no reasons why patients should be denied GP IIb-IIIa inhibitor therapy during their angioplasty procedures." The ESPRIT (Enhanced Suppression of Platelet Receptor GP IIb-IIIa using INTEGRILIN Therapy) study was the first trial designed to assess the efficacy and safety of GP IIb-IIIa inhibitor therapy in patients undergoing non-urgent percutaneous coronary intervention (PCI) with the wide variety of intracoronary stents currently used in clinical practice. In ESPRIT, INTEGRILIN was dosed using an experimental regimen of a 180 mcg/kg bolus, immediately followed by a 2 mcg/kg/min infusion, then followed by a second 180 mcg/kg bolus ten minutes later. The infusion was continued until hospital discharge for up to 18 to 24 hours. On February 4, 2000, an independent Data Safety Monitoring Committee (DSMC) stopped enrollment early in ESPRIT after an interim analysis of 1,758 patients revealed a highly statistically significant reduction in the incidence of death or heart attack at 48 hours with INTEGRILIN as compared to placebo. Analysis of the entire cohort of 2,064 patients enrolled in ESPRIT at the time of study termination documented that the primary endpoint of death, heart attack, need for urgent target vessel revascularization, or need for thrombotic bail-out therapy at 48 hours was reduced with INTEGRILIN from 10.5 percent with placebo to 6.6 percent (P0.0015). The combined incidence of death, heart attack, or need for urgent target vessel revascularization at 30 days was reduced from 10.4 percent with placebo to 6.8 percent with INTEGRILIN (P0.0034). The combined incidence of death or heart attack was reduced from 11.5 percent with placebo to 7.4 percent with INTEGRILIN at 6 months (P0.0015). Consistent with previous clinical trials of GP IIb-IIIa inhibitors, major bleeding, primarily at the site for PCI catheter placement, was increased from 0.4 percent to 1.3 percent. Follow-up information was available for 98.1 percent of all patients at 12 months. Nearly 600,000 percutaneous coronary interventions are performed in the United States each year to restore blood flow through occluded arteries that supply oxygen to heart muscle. More than 60 percent of all PCI procedures employ the use of intracoronary stents, metal mesh structures that hold the artery open after the procedure. Although PCI and intracoronary stenting are generally successful at restoring blood flow and preventing the collapse of the artery, the deployment of the stent into the artery wall can result in the clumping of blood cells called platelets and the development of an intracoronary thrombus or blood clot. Because the thrombus can obstruct blood flow through the artery and thus deprive the heart muscle of oxygen supply, myocardial infarction (heart attack) or death can occur. Some patients may require urgent repeat intervention to reopen the artery. The vast majority of these thrombotic complications take place shortly following the PCI procedure. INTEGRILIN helps prevent reocclusion of the stented artery by blocking certain receptors, known as GP IIb-IIIa, on platelets that are responsible for thrombus development. The effects of INTEGRILIN are exerted at the time of the PCI procedure when the patient is at highest risk.” CORR

Three recent additions to the “A” Portfolio are being reported on.

EMBT ($32.99): News for EMBT: No new news for EMBT> EMBT

PALM ($6.34) News for PALM: No new news for PALM. PALM

CMRC ($8.68): News for CMRC: No new news for CMRC. CMRC

New stocks for this newsletter are: HAND, CHIR, and MLNM.

HAND ($10.31) Handspring, Inc. News for HAND: No new news for HAND. HAND

CHIR ($51.97) Chiron Corp. is a biotechnology company that is developing products for preventing and treating cancer, infectious diseases and cardiovascular disease. News for CHIR: “EMERYVILLE, Calif., May 23 /PRNewswire/ -- Chiron Corporation (Nasdaq: CHIR) announced today that it has reached agreement on definitive licensing terms with F. Hoffmann-La Roche ("Roche") under its human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) intellectual property for nucleic acid testing (NAT) to screen blood, plasma, and blood products intended for transfusion. This agreement will replace the earlier interim licensing arrangement agreed to by Chiron and Roche in October 2000. Roche is now licensed to manufacture and sell probe-based HIV-1 and HCV blood screening tests worldwide, in both single donor and pooled formats, for the life of the patents. This license contains new royalty rates that are based on the number of donations tested and not on test kits sold. These rates will be phased-in during the remainder of 2001, so that by 2002 all probe-based HIV-1 and HCV blood screening tests sold by Roche worldwide will bear royalties under the new agreement. Chiron and Roche have agreed that in certain regions of the world, including Africa and most of Asia, the HIV-1 license will be free of royalties. In addition, the parties have agreed that the HCV royalties will be discounted in these regions. "The safety of blood products worldwide remains a corporate priority for Chiron," commented Sean Lance, Chiron's chairman and chief executive officer. "This agreement ensures that the tests will be provided by Chiron and Roche, guaranteeing a reliable supply structure," Lance continued. "A decade ago, Chiron pioneered HCV immunoassay screening of blood with our partner Johnson & Johnson and our licensee Abbott. Now NAT testing is offered by Chiron with our partner Gen-Probe and our licensee Roche," said Rajen Dalal, president of Chiron's Blood Testing Division. "Both technologies complement each other and help make the blood supply in Europe, North America, Japan, and areas in Asia/Pacific safer than it has ever been. Now our task is to make these tests available in regions where the need remains acute," Dalal continued. In October 2000, the two companies entered broad license agreements covering clinical diagnostics for HIV-1 and HCV. Under the previously announced agreements, Chiron granted Roche worldwide licenses to manufacture and sell probe-based HIV-1 and HCV clinical diagnostic tests covered by Chiron's HIV-1 and HCV patents. At that time, the companies entered into an interim NAT license agreement to permit Roche to continue to serve its blood screening customers while final terms were negotiated.” CHIR

MLNM ($42.04) News for MLNM: No new news for MLNM. MLNM

JDSU ($22.77) JDS Uniphase is a technology company that designs, develops, manufactures and distributes a range of products for the fiberoptic communications market, deployed by systems manufacturers worldwide to develop optical networks.For the 9 months ended 3/31/01, net sales totaled $2.63B, up from $906.4M. Net loss totaled $3.21B, up from $485.9M. Results reflect the acquisitions of E-TEK and SDL, offset by increased amortization and purchased R&D expenses. JDSU

MYGN ($63.10) is engaged in the discovery and sequencing of genes related to major common diseases. MYGN operates a genetic predisposition testing lab and develops products to prevent or treat the diseases associated with these genes. For the 9 months ended 3/31/01, revenues increased 38% to $34.3M. Net loss fell 19% to $5M. Revenues reflect increased research revenue from strategic alliances. Lower loss benefitted from increased interest income. MYGN

PFE ($43.24) Pfizer Inc. is a global pharmaceutical and consumer products company which discovers, develops, manufactures and markets innovative medicines for humans and animals. For the 3 months ended 3/31/01, total revenues rose 7% to $7.65B. Net income totaled $1.93B vs. a loss of $204M. Results reflect increased sales of Lipitor and Norvasc, higher sales of products for Central Nervous System Disorders and the absence of $1.84B in merger-related costs. PFE

With the Market being so volatile, a trader should have some close mental stops in the stocks they buy. We suggest a mental stop of 20% is used where appropriate.

Income and Bonds

We recommend buying utilities based in Florida and not any utilities based in California. The reason is California based utilities do not produce enough of their own power and have to go onto the open market to buy power during peak usage. California utilities are having trouble and two of them Edison Intl. (EIX) and P G & E Corp. (PCG) are having problems so stay away from them for now. PCG has declared bankruptcy last week and Edison Intl. (EIX) has said they will not declare bankruptcy for now. We would stay away from any power generators that supply power to any California utilities at this time. For a person needing some income be sure to look into electric utilities for some bargain buying opportunities to take advantage of the high dividend paying utilities. We would buy 5-year and 10-year treasuries for income and some appreciation if interest rates were lowered more this year. We recommend 3-6 months Treasuries because they are currently yielding 4.0%. CEI yield has gone down to 9.8% but it is still a buy for its yield and our target is $35. We also like these two reits: CRE yielding 6.5% CarrAmerica Realty is a REIT that focuses primarily on the acquisition, development, ownership and operation of office properties in suburban growth markets in the U.S. Forthe FY ended 12/31/00, revenues rose 8% to $558M. Net income from continuing operation fell 3% to $147.2M. Revenues reflect the development of properties being placed in service and higher occupany rate for store properties. Earnings were offset by a lower gain on the sale of assets. CRE and SPG yielding 7.81% Simon Property Group, Inc. is a self-administered and self-managed REIT company, primarily engaged in the expansion & development of real estate properties, primarily malls and shopping centers. For the fiscal year ended 12/31/00, revenues rose 7% to $2.02B. Net income before extra item & acct. change, applic. to Common and limited partners rose 14% to $347.4M. Revenues reflect the CPI merger. Net income reflects gains vs. losses on RE sales. SPG

We have another energy stock we like that has some risk but not as much risk as some of the other energy stocks out in the market. The stock is Entergy (ETR). We added ETR ($44.25) to the “A” Portfolio at $38.50 on April 16th, 2001. News on ETR: No new news for ETR. ETR

Stocks for 2001

The new stocks we have added to our charts for 2001 are: INSP; IMNX; ICOS; TQNT; TGEN; SBUX; RSTA; CRXA; COST; WM; ISLD; MCOM; CHKP; EMLX; ITWO; MANU; JNPR; MUSE; VRTS; QLGC; VRTY; ACRT; AREM; CHCS; INRS; PWER; PDII; SNWL; CHEZ; KO; CORV; GPS; GSPN; MDT; MRCY; AMCC; VTSS; XLNX; BKE; MYGN; CHIR; APC; DVN; JNY; MCLD; NBR; PTEN; QQQ; and TXN. We dropped the following stocks: T; EWEB; ROWE; SGAI; PCOR; PCNTF; ICY; AND LU. You will notice there we be more sections in the charts section of the website. We still will have sections called 12 month, Like, and Tracking. With new sections for Beaten up stocks from 2000, an ADV section for stocks new to our Newsletter, and a section called Dogs of the Dow. Dogs of the Dow are five stocks chosen from the Dow Jones Average of 30 stocks that has shown to beat the market over the past few years.

Some the company’s reports written about Stocks 2001 in the newsletter are here Stock Picks 2001

With the Market being so volatile, a trader should have some close mental stops in the stocks they buy. We suggest a mental stop of 30% is used where appropriate.

Readers will notice all our stocks we follow are on a separate page and we will list prices to purchase stocks at and a target price that we feel the stocks have of reaching in 12 months.

Happy Trading

button

Contact

Make your own free website on Tripod.com